COVID-19 vaccine, drug costs to burden healthcare industry

Once the federal supply of coronavirus vaccines and treatments runs out, health insurers, employers and pharmacy benefit managers must start negotiating with drug manufacturers over prices.

Related Keywords

United States ,America ,Matthew Fiedler ,Amesh Adalja ,Astrazeneca Evusheld ,Brad Ellis ,Centers For Disease ,Fitch Ratings ,Advisory Commission On Immunization Practices ,Drug Administration ,University Of Southern California ,Alliance Of Community Health ,Pfizer ,Bright Health Group ,Human Services Department ,Astrazeneca ,Johns Hopkins Center ,Oscar Health ,Health Security ,Brookings Schaeffer Initiative For Health ,Johnson ,Michael Bagel ,Community Health Plans ,Pharmaceutical Research ,Affordable Care Act ,Disease Control ,Advisory Commission ,